Tudor Investment Corp ET AL lowered its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 16.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,000 shares of the medical research company’s stock after selling 1,722 shares during the period. Tudor Investment Corp ET AL’s holdings in Bio-Rad Laboratories were worth $2,037,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. World Asset Management Inc acquired a new position in Bio-Rad Laboratories in the first quarter valued at approximately $202,000. Quantbot Technologies LP purchased a new stake in Bio-Rad Laboratories in the first quarter valued at $371,000. JPMorgan Chase & Co. lifted its stake in shares of Bio-Rad Laboratories by 1,385.8% in the 1st quarter. JPMorgan Chase & Co. now owns 9,658 shares of the medical research company’s stock valued at $1,925,000 after purchasing an additional 9,008 shares during the last quarter. Prudential Financial Inc. lifted its stake in shares of Bio-Rad Laboratories by 7.6% in the 1st quarter. Prudential Financial Inc. now owns 13,309 shares of the medical research company’s stock valued at $2,653,000 after purchasing an additional 940 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Bio-Rad Laboratories by 123.4% in the 1st quarter. SG Americas Securities LLC now owns 6,248 shares of the medical research company’s stock valued at $1,245,000 after purchasing an additional 3,451 shares during the last quarter. Institutional investors and hedge funds own 62.84% of the company’s stock.

Shares of Bio-Rad Laboratories, Inc. (BIO) traded up 1.59% during mid-day trading on Monday, reaching $225.76. 8,843 shares of the company’s stock were exchanged. The stock has a market cap of $6.69 billion, a price-to-earnings ratio of 446.17 and a beta of 0.91. The stock has a 50 day moving average price of $220.74 and a 200 day moving average price of $217.89. Bio-Rad Laboratories, Inc. has a 52 week low of $154.89 and a 52 week high of $242.79.

A number of research firms have recently weighed in on BIO. Jefferies Group LLC reiterated a “buy” rating and set a $275.00 price target on shares of Bio-Rad Laboratories in a report on Friday, July 14th. Deutsche Bank AG raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and lowered their target price for the stock from $220.00 to $195.00 in a research note on Wednesday, June 28th. BidaskClub raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. TheStreet cut shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Finally, Zacks Investment Research cut shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Bio-Rad Laboratories currently has an average rating of “Buy” and an average target price of $240.80.

In other news, EVP Michael Crowley sold 700 shares of the business’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the completion of the sale, the executive vice president now directly owns 2,060 shares of the company’s stock, valued at approximately $444,774.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 28.29% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Bio-Rad Laboratories, Inc. (BIO) Stake Lessened by Tudor Investment Corp ET AL” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/02/bio-rad-laboratories-inc-bio-stake-lessened-by-tudor-investment-corp-et-al.html.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Stock Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related stocks with our FREE daily email newsletter.